News Overview

EBITDA came in at ₹100.1 crore down 9.6% YoY compared to ₹110.7 crore reflecting operating margin pressure.

Shilpa Medicare said it has completed Phase 3 trials for SMLNUD07 – Nor Ursodeoxycholic Acid (Nor UDCA) tablets in 165 NAFLD patients in India.

EBITDA margin improved to 11.2% vs. 9.7% last year, reflecting better cost management and higher profitability.

So far, the firm had invested about $5 million on pre-development work for a 484 MW wind farm in Mannar and Pooneryn and on the development of Sri Lanka’s 220 KV and 400 KV transmission network.

HAL announced its first interim dividend of ₹25 per equity share for FY25, totaling a payout of over ₹1,600 crore.

On a YoY basis, revenue from operations grew to ₹2,244.9 crore from ₹2,017.2 Cr in Q3 FY24, which translates to an 11.3% increase, indicating steady run-rate business growth

Revenue from operations of the company stood at ₹307.2 crore, with a Year-on-Year (YoY) growth of 39.8% quarter over Q3 FY24 as compared to ₹219.8 crore

Ayana Renewable Power is among India’s major renewable energy organizations, primarily focused on large-scale solar and wind projects.

The company stated that its revenue from operations witnessed growth of 34.40% at ₹4,824.80 Crore during the period under review.

As part of the collaboration, both companies aim to jointly explore and identify commercial opportunities across different verticals of the BESS value chain.